Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation

Huan He, Carol L. Nilsson, Mark Emmett, Alan G. Marshall, Roger A. Kroes, Joseph R. Moskal, Yongjie Ji, Howard Colman, Waldemar Priebe, Frederick F. Lang, Charles A. Conrad

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

A glioblastoma stem cell (GSC) line, GSC11, grows as neurospheres in serum-free media supplemented with EGF (epidermal growth factor) and bFGF (basic fibroblast growth factor), and, if implanted in nude mice brains, will recapitulate high-grade glial tumors. Treatment with a STAT3 (signal transducer and activator of transcription 3) phosphorylation inhibitor (WP1193) or 10% FBS (fetal bovine serum) both led to a decrease in expression of the stem cell marker CD133 in GSC11 cells, but differed in phenotype changes. Altered glycolipid profiles were associated with some differentially expressed glycogenes. In serum treated cells, an overall increase in glycosphingolipids may be due to increased expression of ST6GALNAC2, a sialyltransferase. Serum treated cells express more phosphatidylcholine (PC), short chain sphingomyelin (SM) and unsaturated long chain phosphatidylinositol (PI). Decrease of a few glycosphingolipids in the STAT3 phosphorylation inhibited cells may be linked to decreased transcripts of ST6GALNAC2 and UGCGL2, a glucosylceramide synthase. A rare 3-sulfoglucuronylparagloboside carrying HNK1 (human natural killer-1) epitope was found expressed in the GSC11 and the phenotypically differentiated cells. Its up-regulation correlates with increased transcripts of a HNK1 biosynthesis gene, B3GAT2 after serum treatment. Taken together with a quantitative phosphoproteomic study of the same GSC line (C. L. Nilsson, et al. J. Proteome Res. 2010, 9, 430-443), this report represents the most complete systems biology study of cancer stem cell (CSC) differentiation to date. The synergies derived by the combination of glycomic, transcriptomic and phosphoproteomic data may aid our understanding of intracellular and cell-surface events associated with CSC differentiation.

Original languageEnglish (US)
Pages (from-to)2098-2108
Number of pages11
JournalJournal of Proteome Research
Volume9
Issue number5
DOIs
StatePublished - May 7 2010
Externally publishedYes

Fingerprint

Glycomics
STAT3 Transcription Factor
Phosphorylation
Glioblastoma
Stem cells
Stem Cells
Glycosphingolipids
Serum
ceramide glucosyltransferase
Neoplastic Stem Cells
Cells
Cell Differentiation
Sialyltransferases
Sphingomyelins
Glycolipids
Biosynthesis
Serum-Free Culture Media
Cell Line
Fibroblast Growth Factor 2
Proteome

Keywords

  • 3-sulfoglucuronylparagloboside
  • Cancer stem cells
  • FT- ICR MS
  • Glioma
  • Glycolipids
  • HNK1
  • Lipidomics
  • Metabolomics
  • Phospholipids
  • Transcriptomics

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Cite this

Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. / He, Huan; Nilsson, Carol L.; Emmett, Mark; Marshall, Alan G.; Kroes, Roger A.; Moskal, Joseph R.; Ji, Yongjie; Colman, Howard; Priebe, Waldemar; Lang, Frederick F.; Conrad, Charles A.

In: Journal of Proteome Research, Vol. 9, No. 5, 07.05.2010, p. 2098-2108.

Research output: Contribution to journalArticle

He, H, Nilsson, CL, Emmett, M, Marshall, AG, Kroes, RA, Moskal, JR, Ji, Y, Colman, H, Priebe, W, Lang, FF & Conrad, CA 2010, 'Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation', Journal of Proteome Research, vol. 9, no. 5, pp. 2098-2108. https://doi.org/10.1021/pr900793a
He, Huan ; Nilsson, Carol L. ; Emmett, Mark ; Marshall, Alan G. ; Kroes, Roger A. ; Moskal, Joseph R. ; Ji, Yongjie ; Colman, Howard ; Priebe, Waldemar ; Lang, Frederick F. ; Conrad, Charles A. / Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. In: Journal of Proteome Research. 2010 ; Vol. 9, No. 5. pp. 2098-2108.
@article{6b68fbef0b2d446babf82656df913121,
title = "Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation",
abstract = "A glioblastoma stem cell (GSC) line, GSC11, grows as neurospheres in serum-free media supplemented with EGF (epidermal growth factor) and bFGF (basic fibroblast growth factor), and, if implanted in nude mice brains, will recapitulate high-grade glial tumors. Treatment with a STAT3 (signal transducer and activator of transcription 3) phosphorylation inhibitor (WP1193) or 10{\%} FBS (fetal bovine serum) both led to a decrease in expression of the stem cell marker CD133 in GSC11 cells, but differed in phenotype changes. Altered glycolipid profiles were associated with some differentially expressed glycogenes. In serum treated cells, an overall increase in glycosphingolipids may be due to increased expression of ST6GALNAC2, a sialyltransferase. Serum treated cells express more phosphatidylcholine (PC), short chain sphingomyelin (SM) and unsaturated long chain phosphatidylinositol (PI). Decrease of a few glycosphingolipids in the STAT3 phosphorylation inhibited cells may be linked to decreased transcripts of ST6GALNAC2 and UGCGL2, a glucosylceramide synthase. A rare 3-sulfoglucuronylparagloboside carrying HNK1 (human natural killer-1) epitope was found expressed in the GSC11 and the phenotypically differentiated cells. Its up-regulation correlates with increased transcripts of a HNK1 biosynthesis gene, B3GAT2 after serum treatment. Taken together with a quantitative phosphoproteomic study of the same GSC line (C. L. Nilsson, et al. J. Proteome Res. 2010, 9, 430-443), this report represents the most complete systems biology study of cancer stem cell (CSC) differentiation to date. The synergies derived by the combination of glycomic, transcriptomic and phosphoproteomic data may aid our understanding of intracellular and cell-surface events associated with CSC differentiation.",
keywords = "3-sulfoglucuronylparagloboside, Cancer stem cells, FT- ICR MS, Glioma, Glycolipids, HNK1, Lipidomics, Metabolomics, Phospholipids, Transcriptomics",
author = "Huan He and Nilsson, {Carol L.} and Mark Emmett and Marshall, {Alan G.} and Kroes, {Roger A.} and Moskal, {Joseph R.} and Yongjie Ji and Howard Colman and Waldemar Priebe and Lang, {Frederick F.} and Conrad, {Charles A.}",
year = "2010",
month = "5",
day = "7",
doi = "10.1021/pr900793a",
language = "English (US)",
volume = "9",
pages = "2098--2108",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation

AU - He, Huan

AU - Nilsson, Carol L.

AU - Emmett, Mark

AU - Marshall, Alan G.

AU - Kroes, Roger A.

AU - Moskal, Joseph R.

AU - Ji, Yongjie

AU - Colman, Howard

AU - Priebe, Waldemar

AU - Lang, Frederick F.

AU - Conrad, Charles A.

PY - 2010/5/7

Y1 - 2010/5/7

N2 - A glioblastoma stem cell (GSC) line, GSC11, grows as neurospheres in serum-free media supplemented with EGF (epidermal growth factor) and bFGF (basic fibroblast growth factor), and, if implanted in nude mice brains, will recapitulate high-grade glial tumors. Treatment with a STAT3 (signal transducer and activator of transcription 3) phosphorylation inhibitor (WP1193) or 10% FBS (fetal bovine serum) both led to a decrease in expression of the stem cell marker CD133 in GSC11 cells, but differed in phenotype changes. Altered glycolipid profiles were associated with some differentially expressed glycogenes. In serum treated cells, an overall increase in glycosphingolipids may be due to increased expression of ST6GALNAC2, a sialyltransferase. Serum treated cells express more phosphatidylcholine (PC), short chain sphingomyelin (SM) and unsaturated long chain phosphatidylinositol (PI). Decrease of a few glycosphingolipids in the STAT3 phosphorylation inhibited cells may be linked to decreased transcripts of ST6GALNAC2 and UGCGL2, a glucosylceramide synthase. A rare 3-sulfoglucuronylparagloboside carrying HNK1 (human natural killer-1) epitope was found expressed in the GSC11 and the phenotypically differentiated cells. Its up-regulation correlates with increased transcripts of a HNK1 biosynthesis gene, B3GAT2 after serum treatment. Taken together with a quantitative phosphoproteomic study of the same GSC line (C. L. Nilsson, et al. J. Proteome Res. 2010, 9, 430-443), this report represents the most complete systems biology study of cancer stem cell (CSC) differentiation to date. The synergies derived by the combination of glycomic, transcriptomic and phosphoproteomic data may aid our understanding of intracellular and cell-surface events associated with CSC differentiation.

AB - A glioblastoma stem cell (GSC) line, GSC11, grows as neurospheres in serum-free media supplemented with EGF (epidermal growth factor) and bFGF (basic fibroblast growth factor), and, if implanted in nude mice brains, will recapitulate high-grade glial tumors. Treatment with a STAT3 (signal transducer and activator of transcription 3) phosphorylation inhibitor (WP1193) or 10% FBS (fetal bovine serum) both led to a decrease in expression of the stem cell marker CD133 in GSC11 cells, but differed in phenotype changes. Altered glycolipid profiles were associated with some differentially expressed glycogenes. In serum treated cells, an overall increase in glycosphingolipids may be due to increased expression of ST6GALNAC2, a sialyltransferase. Serum treated cells express more phosphatidylcholine (PC), short chain sphingomyelin (SM) and unsaturated long chain phosphatidylinositol (PI). Decrease of a few glycosphingolipids in the STAT3 phosphorylation inhibited cells may be linked to decreased transcripts of ST6GALNAC2 and UGCGL2, a glucosylceramide synthase. A rare 3-sulfoglucuronylparagloboside carrying HNK1 (human natural killer-1) epitope was found expressed in the GSC11 and the phenotypically differentiated cells. Its up-regulation correlates with increased transcripts of a HNK1 biosynthesis gene, B3GAT2 after serum treatment. Taken together with a quantitative phosphoproteomic study of the same GSC line (C. L. Nilsson, et al. J. Proteome Res. 2010, 9, 430-443), this report represents the most complete systems biology study of cancer stem cell (CSC) differentiation to date. The synergies derived by the combination of glycomic, transcriptomic and phosphoproteomic data may aid our understanding of intracellular and cell-surface events associated with CSC differentiation.

KW - 3-sulfoglucuronylparagloboside

KW - Cancer stem cells

KW - FT- ICR MS

KW - Glioma

KW - Glycolipids

KW - HNK1

KW - Lipidomics

KW - Metabolomics

KW - Phospholipids

KW - Transcriptomics

UR - http://www.scopus.com/inward/record.url?scp=77952077198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952077198&partnerID=8YFLogxK

U2 - 10.1021/pr900793a

DO - 10.1021/pr900793a

M3 - Article

VL - 9

SP - 2098

EP - 2108

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 5

ER -